1. Company

Company

Founded as the first on-campus startup
at Seoul National University in 1996. ​

개인정보처리방침

닫기

이메일무단수집거부

닫기

Helixmith has expanded its products and pipelines with biologics and natural nutraceutical.​

Helixmith’s lead gene therapy product in the biologics business is Engensis (VM202), currently in phase III diabetic peripheral neuropathy (DPN) in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF), HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers (DFU), amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease (CMT).

​ Helixmith has the experience and capabilities necessary to advance a product through the entire drug development process. Helixmith is focused on developing innovative products to address unmet needs in both chronic and rare diseases​

Helixmith is also developing natural bionutricals with excellent efficacy and low side effects, utilizing experience and knowledge in research and development accumulated over the past 20 years. The company has unique experience in areas including natural medicine, health functional food and cosmetic products using botanical sources.​

Helixmith possesses the organization and abilities that exceeds most leading global biotech companies. The company has experience in basic science, candidate screening, preclinical, analytical processing, production, quality control, regulatory and clinical development. Helixmith will continue to strengthen our pipelines with new technologies and knowledge to maintain a high growth and create a high revenue business.​

  • Corporate name

    HELIXMITH​

  • CEO​

    Sunyoung Kim​,
    Seungshin Yu​

  • Date of establishment​

    November 21, 1996​
    (Date of IPO : 29 December 2005)​

  • Location​

    21, Magokjungang 8-ro 7-gil,
    Gangseo-gu Seoul 07794, Korea​

    4275 Executive Square Unit 200,
    La Jolla, CA 92037

  • Major Business

    Bio products ​
    Natural Bionutricals​